Hypoglycemic Events in Diabetic Patients under Non-insulin Regimens During Ramadan: A Frequentist Network Meta-Analysis

Salah Eddine O. Kacimi¹⁺, MD, Mahnoor Sukaina²⁺, MBBS, Anas Elgenidy³⁺, MBBS, Ramadan Abdelmoez Farahat⁴, MBBS, Huzaifa A. Cheema⁵, MBBS, Amira Y. Benmelouka⁶, MD, Dina M. Awad⁷, MD; Hadj Ahmed Belaouni⁸, PhD, Moustafa K.E Abdelli¹, MD, Anisse Tidjane⁹, MD, Nabil Smain Mesli^{1,10}, MD, Jaffer Shah^{11*}, MD, Mounir Ould Setti¹², MD, Ahmed M. Afifi¹³, MBBS, Sherief Ghozy^{14,15}, MD & the Ramadan Diabetes Research Group (RDRG) Collaborators[#]

⁺Co-first authors

¹ Faculty of Medicine, Abou-Bekr Belkaid University of Tlemcen, Tlemcen, Algeria

² Faculty of Medicine, Karachi Medical and Dental College, Karachi, Pakistan

³ Faculty of Medicine, Cairo University, Cairo, Egypt

⁴ Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt

⁵ Department of Medicine, King Edward Medical University, Lahore, Pakistan

⁶ Faculty of Medicine, University of Algiers, Algiers, Algeria

⁷ Alexandria Faculty of Medicine, Alexandria University, Alexandria, Egypt

⁸ Laboratoire de Biologie des Systèmes Microbiens (LBSM), Ecole Normale Supérieure de Kouba, Algiers, Algeria

⁹ Faculty of Medicine, University of Oran, Oran, Algeria

¹⁰ Department of Surgery A, University-Hospital Center (CHU) of Tlemcen, Tlemcen, Algeria

¹¹ Medical Research Center, Kateb University, Kabul, Afghanistan

¹² Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland

¹³ Division of gastroenterology, Baylor College of Medicine, Texas, USA

¹⁴ Department of Radiology, Mayo Clinic, Rochester, MN, USA

¹⁵ Nuffield Department of Primary Care Health Sciences and Department for Continuing Education (EBOHE: priogram), reputies review and should not be used to guide clinical practice.

*Corresponding authors

[#] Ramadan Diabetes Research Group (RDRG) Collaborators (PubMed-Indexed): Hazem S. Ghaith, Mostafa Reda, Ian SOH

Corresponding author

Jaffer Shah, MD

Medical Research Center, Kateb University, Kabul, Afghanistan; Jaffer.shah@kateb.edu.af

1 Abstract

2 <u>Background</u>

3 Diabetic Muslims who choose to fast during Ramadan encounter major risks such as 4 hyperglycemia, hypoglycemia, diabetic ketoacidosis, and dehydration. Recently, newer 5 antidiabetic agents have been found to be less likely to cause hypoglycemic emergencies. This 6 meta-analysis aimed to present collective and conclusive results from major randomized 7 controlled trials (RCTs) to determine the risk of hypoglycemia among patients taking oral 8 antidiabetics during Ramadan.

9 <u>Methods</u>

We searched PubMed, Web of Science, and Google Scholar for RCTs. We performed a frequentist network meta-analysis using the "netmeta" package of R software version 4.1.1 to investigate the risk of developing hypoglycemia after taking oral antidiabetic drugs during Ramadan.

14 <u>Results</u>

Nine RCTs with a total of 3464 patients were included in the final analysis. In the comparison of all antidiabetic drug classes with sulfonylureas, SGLT-2 inhibitors were associated with the lowest hypoglycemic risk (RR, 0.18; 95% CI, 0.04-0.78; P-score, 0.909), followed by GLP-1 agonists (RR, 0.31; 95% CI, 0.17-0.56; P-score, 0.799), and DDP-4 inhibitors (RR, 0.57; 95% CI, 0.43-0.75; P-score, 0.483). When comparing individual drugs, dapagliflozin was associated with the lowest hypoglycemic risk (RR, 0.18; 95% CI, 0.04-0.78; P-score, 0.874), followed by lixisenatide (RR, 0.25; 95% CI, 0.09-0.71; P-score, 0.813), liraglutide (RR, 0.34; 95% CI, 0.17-

- 22 0.69; P-score, 0.715), and sitagliptin (RR. 0.51; 95% CI, 0.37-0.71; P-score, 0.515).
- 23 <u>Conclusion</u>
- 24 SGLT-2 inhibitors are associated with the least documented hypoglycemic events and adverse
- 25 outcomes compared with other oral hypoglycemic drugs. These findings could have considerable
- 26 public health and clinical implications when extrapolated to the global Muslim population with a
- 27 similar clinical background.
- 28 <u>Keywords</u>
- 29 SGLT-2 inhibitors; Ramadan fasting; Diabetic Muslims; Hypoglycemia; Non-insulin Regimen;
- 30 Frequentist Network Meta-Analysis

Visual Abstract		ntidiabetics during	1 8
🕻 Summary	symptomatic hypoglycem type II diabetic patients w	P-4 inhibitors were associated wi nic events during Ramadan comp vith most reduction benefit seen v ar among the interventions and c	ared to SU among 💛 vith SGLT-2.
	atic review with meta-analysis	Studies reporting particip symptomatic hypoglycem	WERE OLD WAR
		ean age Median female 3.8 years 50% Women	Mean BMI 29.6 kg/m2
	erventions uphonylurea such as Glimepride SGLT-2 Inhibitors Network meta-analy	A Inhibitors 3 DDP-4 Inhibitors 1 Meglinide (Repaglinide)	Comparator ulphonylurea
-	Symptomatic HG	Any adverse event	Evidence score
SGLT-2 inhibitors GLP-1 inhibitors DDP-4 inhibitors Meglitinide Graphics by: S.E.O Kacimi, H.A. Belao	I 2 3 uni	0 1 2 3 Moderate	

32 Introduction

Fasting is one of the basic principles of Islam, a religion that over a billion people practice. Healthy Muslim adults must cease eating and drinking from sunrise to sunset during Ramadan, the 9th lunar month in the Islamic calendar [1,2]. Presently, there are more than 150 million Muslim diabetics globally [3], and the number of diabetics worldwide is expected to surpass 360 million by 2030 [2]. Glycemic control in diabetic patients is essential. This is to avoid acute hyperosmolar non-ketotic coma, chronic diabetic complications such as diabetic retinopathy in microvascular changes, and other macrovascular complications [1].

However, maintaining glycemic control may be difficult, especially for diabetic Muslims who 40 fast during the holy month of Ramadan.[4] Therein lies the major and serious complication of 41 hypoglycemia associated with fasting and oral hypoglycemic antidiabetic such as meglitinides 42 and sulfonylureas [1,5,6]. The Epidemiology of Diabetes and Ramadan (EPIDIAR) 43 demonstrated that around 78.5% of Muslim diabetic patients who fast did not refrain from 44 fasting for at least 15 days. Furthermore, an alteration in physical activity and changes in insulin 45 dosage and other oral hypoglycemic drugs were observed to increase severe hypoglycemic 46 47 events [7].

In recent times, newer antidiabetic agents have been introduced which are less likely to cause 48 49 hypoglycemic emergencies. Such antidiabetics include dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose co-transporter-2(SGLT-2) inhibitors. Crucially, the role of SGLT-2 50 51 inhibitors has been rarely elaborated in a network meta-analysis to show efficacy in fasting diabetic patients. Currently, most studies have shown that hypoglycemia during Ramadan can be 52 curbed by shifting the therapy from insulin or other oral hypoglycemics to DPP-4 inhibitors or 53 metformin [1,5,6]. A network meta-analysis by Lee et al. showed that newer antidiabetics exhibit 54 appropriate glycemic control and lower hypoglycemic complications than sulfonylureas [8]. 55 Moreover, it also highlighted that incretin-based mimetics manifest 1.5 times lesser 56 hypoglycemic events [8]. Likewise, a recent meta-analysis demonstrated that DPP-4 and 57 glucagon-like peptide (GLP-1) agonist therapy significantly improves HbA1c levels amongst 58 fasting diabetic patients during Ramadan [9]. Other studies have also shown that Ramadan-59 focused diabetes education helps create awareness among the population, ensuring a decline in 60 HbA1c levels in fasting patients [10]. 61

This systematic review and meta-analysis aimed to present collective and conclusive results of major randomized controlled trials (RCTs) regarding hypoglycemic events associated with antidiabetic medication in the fasting population during Ramadan. Diabetic emergencies, if not treated timely, can lead to fatal outcomes. Lack of awareness and standard therapy hinders seeking and continuing treatment. The rationale of our study is to fill the literature gap and provide the data that helps create a standardized therapy for fasting people with diabetes during Ramadan.

69 Methods

70 This meta-analysis was conducted according to the Preferred Reporting Items for Systematic

71 Review and Meta-analyses (PRISMA) statement recommendations [11]. A systematic search

was done to select all the trials that correspond to the following criteria: 1) population: diabetics

73 fasting during Ramadan; 2) intervention and comparator: any non-insulin oral antidiabetic agent

compared with another oral agent; 3) outcome: hypoglycemic events; and 4) study design: RCTs.

75 Literature search

76 The search was conducted on March 2022 in the following databases: MEDLINE (via PubMed),

Scopus, Web of Science, and Science Direct using a search string relating to the followingkeywords: Ramadan, diabetes, oral antidiabetic agents, and hypoglycemia.

There were no restrictions on language, country, gender, race, or sample size among the published articles. Animal reports, reviews, letters, commentaries, conference abstracts/posters, case reports, case series, and trials including diabetic patients not fasting in Ramadan were excluded. Further, a manual search of reference lists of the included studies was done to retrieve any relevant studies.

84 Screening and study selection

After removing duplicates, the title and abstract screening of the selected articles was performed by two independent reviewers. This step was followed by a full-text screening of the selected articles to verify the included population and the availability of the outcomes. When full texts were not available, we contacted the authors. Disagreements were resolved by a third senior researcher.

90 Data extraction

91 Two independent authors performed the data extraction using a pre-performed excel sheet.

92 Population demographics and data on hypoglycemic events during Ramadan were extracted.

93 Disagreements were resolved through discussion with a senior researcher to find a consensus.

94 Risk of bias

95 Two independent investigators evaluated the risk of bias in the included studies using the revised Cochrane Risk of Bias Tool for randomized controlled trials (RoB 2.0) [12]. RoB 2.0 addresses 96 five domains: (1) bias arising from the randomization process; (2) bias due to deviations from 97 98 intended interventions; (3) bias due to missing outcome data; (4) bias in measurement of the outcome; and (5) bias in the selection of the reported result. Each item was described as having a 99 low, high, or unclear risk of bias. Each study's overall risk of bias was described as low, 100 moderate, or high risk, based on our judgments for all the items. A senior author resolved any 101 discrepancies among reviewers by consensus. 102

103 Statistical analysis

104 We conducted the analysis using the 'netmeta' package ver. 2.1-0 (<u>https://cran.r-</u> 105 <u>project.org/web/packages/netmeta/index.html</u>) of R software version 4.1.1. We performed a

106 frequentist network meta-analysis to investigate the risk of developing hypoglycemia after taking

- 107 oral antidiabetic drugs during Ramadan. Fixed- or random-effects models were used to perform
- the network meta-analysis based on the level of heterogeneity/inconsistency [13]. When ≥ 10
- studies were available, we built comparison-adjusted funnel plots to examine small study effects
- 110 [13]. Funnel plot asymmetry was assessed with three tests (Begg-Mazumdar test, Egger's
- regression, and Thompson–Sharp test). P values <0.1 were considered significant [14–16].

112 **Results**

113 **Description of Eligible Trials**

After screening, nine studies were selected for final analysis [17–25] (Fig. 1). Five studies were 114 multi-centric and conducted in several countries while the rest were conducted in the UK, 115 116 Lebanon, Malaysia, India, and Malaysia. All included studies were RCTs with double arm comparisons with sulfonylureas (Fig. 2). The total number of patients was 3464, with 1743 in the 117 sulfonylurea treated group (mean age=53.6), and 1721 (mean age=53.9) in the intervention 118 group. The intervention group included patients treated with the following drugs: sitagliptin, 119 120 liraglutide, vildagliptin, lixisenatide and basal insulin, repaglinide, and dapagliflozin plus metformin. The mean BMIs for the intervention and sulfonylurea treated groups were 29.7 and 121 29.4, respectively (Tab. 1). 122

123 Results of the Outcomes in NMA

124 Hypoglycemia risk

Among the diabetic patients, the network of treatment comparisons for hypoglycemia was 125 reported in nine studies [17–25]. The sulfonylurea was the well-connected group directly linked 126 127 to all other treatments. In the comparison of all antidiabetic drug classes with sulfonylureas, SGLT-2 inhibitors were associated with the lowest hypoglycemic risk (RR, 0.18; 95% CI, 0.04-128 129 0.78; P-score, 0.909), followed by GLP-1 agonists (RR, 0.31; 95% CI, 0.17-0.56; P-score, 0.799), and DDP-4 inhibitors (RR, 0.57; 95% CI, 0.43-0.75; P-score, 0.483). Compared with 130 each other, SGLT-2 inhibitors, GLP-1 agonists, DDP-4 inhibitors, and meglitinide did not reveal 131 a statistically significant difference (Fig. 3). 132

Dapagliflozin was associated with the lowest hypoglycemic risk (RR, 0.18; 95% CI, 0.04-0.78; P-score, 0.874), followed by lixisenatide (RR, 0.25; 95% CI, 0.09-0.71; P-score, 0.813), liraglutide (RR, 0.34; 95% CI, 0.17-0.69; P-score, 0.715), and sitagliptin (RR. 0.51; 95% CI, 0.37-0.71; P-score, 0.515), Ranking of the risk of hypoglycemia using p-score revealed dapagliflozin as the best, and sulfonylureas as the worst among treatments (P-score, 0.093). Compared with each other, dapagliflozin, lixisenatide, liraglutide, sitagliptin, vildagliptin, and repaglinide did not reveal a statistically significant difference (**Fig. 4**).

140 Adverse effects

141 Comparing all treatments with sulfonylureas, there were almost no statistically significant 142 differences regarding the relative risk of having any adverse event (**Fig. 5**). However, ranking the

risk of any adverse events using P-scores revealed sulfonylurea as the best (P-score, 0.59), with

- 144 fewer adverse events, and GLP-1 agonists as the worst among treatments (P-score, 0.38). There
- 145 was no statistically significant difference between the drug classes compared to each other.

146 Risk of Bias of Included Studies

- 147 The quality of included studies ranged from moderate to high quality according to the Cochrane
- 148 Collaboration's tool for assessing the risk of bias 2 (RoB 2).
- 149 Regarding the randomization process, four studies were of low risk of bias [17,19,21,22], while
- 150 five studies [18,20,23–25] were judged to have some concerns due to the lack of blinding
- 151 patients and the study personnel.
- 152 All included trials had a low risk of bias in terms of deviations from the intended interventions,
- the missing outcome data, the measurement outcome bias, and the selection of the reported
- results bias. The detailed risk of bias domains by study ID, are reported in the supplement.

155 Sensitivity Analyses

We compared the individual drugs of the sulfonylurea class with other antidiabetic drugs. The network of treatment comparisons for hypoglycemia consisted of eight individual nodes.

- 158 Gliclazide was the well-connected group and directly linked to all other treatments.
- In the comparison of all individual drugs with glibenclamide, liraglutide was associated with the lowest hypoglycemic risk (RR, 0.12; 95% CI, 0.03-0.49; P-score, 0.92), followed by lixisenatide (RR, 0.15; 95% CI, 0.04-0.62; P-score, 0.88), sitagliptin (RR, 0.43; 95% CI, 0.21-0.87; P-score, 0.60), vildagliptin (RR. 0.43; 95% CI, 0.12-1.48; P-score,0.57), gliclazide (RR, 0.61; 95% CI, 0.29-1.25; P-score, 0.40), glimepiride (RR. 0.74; 95% CI, 0.39-1.42; P-score,0.28), and repaglinide (RR, 0.95; 95% CI, 0.27-3.10; P-score, 0.23; **Fig. 6**). Ranking of the risk of any adverse events using p-score revealed liraglutide as the best, being with fewer hypoglycemic
- events, and glibenclamide as the worst among treatments (P-score, 0.117).

Among incretins mimetics, Liraglutide was better than lixisenatide, but there was no statistically significant difference regarding hypoglycemic events. Liraglutide and lixisenatide were better than **sulfonylureas** (gliclazide and glimepiride, glibenclamide), with statistically significant differences. Both Liraglutide and lixisenatide were better than **repaglinide**, but Liraglutide showed a statistically significant difference compared with repaglinide but not lixisenatide. Finally, Liraglutide and lixisenatide were better than **DPP-4 inhibitors** (sitagliptin, vildagliptin) with no statistically significant difference.

Among DPP-4 inhibitors, Sitagliptin was better than vildagliptin, with no statistically significant difference between them regarding the hypoglycemic events. Sitagliptin and vildagliptin were better than **sulfonylureas drugs** (Gliclazide and glimepiride, glibenclamide), with a statistically significant difference only between Sitagliptin and glibenclamide. Sitagliptin and vildagliptin were better than **repaglinide** with no statistically significant difference between them.

Among sulfonylureas, Gliclazide was better than glimepiride, and glibenclamide with no statistically significant difference between them regarding the hypoglycemic events. Both Gliclazide and glimepiride were better than **repaglinide**, on the other hand, repaglinide is better than glibenclamide. However, there was no statistically significant difference between them regarding the hypoglycemic events (**Fig. 6**).

185

186 **Discussion**

To the best of our knowledge, this is the first network meta-analysis of all newer oral 187 hypoglycemic agents explicating hypoglycemic events in fasting diabetic patients during 188 189 Ramadan. We found that SGLT-2 inhibitors are associated with the least documented hypoglycemic events and adverse outcomes followed by GLP-1 agonists, DPP-4 inhibitors, 190 meglitinide and sulfonylureas. A recent meta-analysis by Gad et al. advocates the treatment 191 efficacy of SGLT-2 inhibitors in Ramadan with fewer major adverse events [26]. Other meta-192 analyses by Shiju et al. and Loh et al.promote treatment with vildagliptin in high-risk patients, 193 194 especially the elderly [27,28].

Original studies reporting that vildagliptin is associated with lesser hypoglycemic events during 195 Ramadan coincide with our results [21,29,30]. However, when comparing both classes, 196 vildagliptin has slighter lower efficacy as compared to sitagliptin, but non-significant better 197 results than sulfonylureas. Gad et al. elucidated similar outcomes that favor the efficacy of 198 SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors; however, the study does not ascertain 199 the efficiency of newer oral hypoglycemic in the hierarchy of least hypoglycemic 200 events.[9]Furthermore, the meta-analysis by Gad et al. approves both lixisenatide and liraglutide 201 for fasting diabetic patients in Ramadan like our study. Similarly, a meta-analysis by Gray et al. 202 presented the clinical efficacy of liraglutide [31]. We demonstrate that lixisenatide shows better 203 efficacy than liraglutide; however, both lower risk of symptomatic hypoglycemia compared with 204 sulfonylureas. 205

206 We acknowledge the statement by Gray et al. that the majority of trials and observational studies favor the treatment efficacy of DPP-4 inhibitors over sulfonylureas in fasting T2D patients [31]. 207 208 Our meta-analysis shows the possible efficacy of SGLT-2 inhibitors over GLP-1 agonists and the aforementioned drugs over DPP-4 inhibitors, although all these drug classes are advantageous in 209 210 preventing hypoglycemic events in fasting diabetics. However, like Gray et el. we recommend that in the future, more studies should evaluate and compare SGLT-2 inhibitors, GLP-1 agonists, 211 and DPP-4 inhibitors in terms of efficacy, effectiveness, primary and secondary outcomes, and 212 safety outcomes. A study by Lee et al. showed that DPP-4 inhibitors can reduce the occurrence 213 of hypoglycemic events in people who fast during Ramadan when compared to sulfonylureas [8]. 214 However, it was inconclusive regarding meglitinides due to the lack of relevant data on people 215 observing fasting. The study by Mbanya et al. compared sulfonylureas and found gliclazide to be 216 the better choice of drug as compared with glimepiride which is better when compared to 217 metformin [32]. On the contrary, the observation study by Bonakdaran and Khajeh-Dalouie 218

concluded that sulfonylureas have a significantly higher incidence of hypoglycemic events as 219 compared to metformin [33]. The LIRA-Ramadan study by Azar et al. concluded that using 220 liraglutide can have significantly better outcomes and lesser complications, including 221 hypoglycemic events, compared with sulfonylureas [23]. Similarly, our study shows that GLP-1 222 223 agonists have better outcomes when compared with DPP-4 inhibitors, meglitinides, and sulfonylureas. John et al. discussed that SGLT-2 inhibitors provide lesser risk or severity of 224 hypoglycemia in patients living in warm climate conditions [34]. The majority of Muslims live 225 in warm climatic conditions, and therefore fasting in Ramadan has better results when people are 226 using SGLT-2 inhibitors and may reduce the risk of hypoglycemia. 227

- Currently, amidst the COVID-19 pandemic, Tootee et al. discussed that SGLT-2 inhibitors be avoided due to the heightened risk of diabetic ketoacidosis (DKA) and dehydration as COVID-19 infection may cause compromised immunity [35]. Hassanein et al., in their CRATOS study, concluded that SGLT-2 inhibitors are a safer option for people fasting in Ramadan as they have a lower incidence of hypoglycemic events [36]. However, they still have the risk of volume
- depletion due to osmotic diuresis, especially in the elderly group of patients [37].
- We recommend using newer technology, non-invasive devices over the regular finger prick glucometers to monitor glucose levels throughout the day in fasting diabetics, which will aid in prick-free testing without voiding the fast and help recognize the best possible management regimen of diabetic drugs for individuals with different co-morbidities [38]. These devices can read glucose levels 24 hours a day and keep-up the track for up to two weeks.

239 Strengths and Limitations

We presented a network meta-analysis of associations of different newer oral hypoglycemic 240 241 drugs with the extent of hypoglycemia and adverse events from multicenter studies in different races and populations. Several limitations we observed include only hypoglycemic events as our 242 243 outcome and not changes in HbA1c, weight loss, and changes in systolic and diastolic blood pressures. Moreover, we presented general adverse events and did not specify the most to least 244 common adverse events associated with each drug class. We specified different drugs in each 245 class, but we were only able to evaluate the efficacy of dapagliflozin in the class of SGLT-2 246 inhibitors. Another limitation that needs to be pointed out is the scarcity of studies on this topic 247 with only nine trials matching our selection criteria. 248

249 OTHER INFORMATION

250 Financial support

251 This work is not supported by any third party.

252 Conflict of interest

253 The authors of this work have no competing interests to declare.

254 Availability of data, code, and other materials

255 Data of this study are available upon reasonable request from the corresponding author.

256 **References**

- 257 [1] Abdessadek M, Khabbal Y, Magoul R, Marmouzi I, Ajdi F. Follow-up of glycemic index
- before and after Ramadan fasting in type 2 diabetes patients under antidiabetic
- 259 medications. Ann Pharm Françaises 2019;77:374–81.
- 260 https://doi.org/https://doi.org/10.1016/j.pharma.2019.04.003.
- 261 [2] Mudher Mikhael E. Effectiveness and Safety of Newer Antidiabetic Medications for
- Ramadan Fasting Diabetic Patients. J Diabetes Res 2016;2016:6962574.
- 263 https://doi.org/10.1155/2016/6962574.
- 264 [3] Diabetes and Ramadan n.d. https://idf.org/our-activities/education/diabetes-and-
- ramadan.html (accessed May 27, 2022).
- 266 [4] Almalki MH, Alshahrani F. Options for Controlling Type 2 Diabetes during Ramadan .
- Front Endocrinol 2016;7.
- 268 [5] Aziz KM. Fasting during Ramadan: efficacy, safety, and patient acceptability of
- vildagliptin in diabetic patients. Diabetes Metab Syndr Obes 2015;8:207–11.
- 270 https://doi.org/10.2147/DMSO.S54683.
- 271 [6] Loh HH, Kamaruddin NA. Treatment Options for Patients with Type 2 Diabetes Mellitus
- during the Fasting Month of Ramadan. Ann Acad Med Singapore 2020;49:468–76.
- 273 [7] Salti I, Bénard E, Detournay B, Bianchi-Biscay M, Le Brigand C, Voinet C, et al. A
- 274 population-based study of diabetes and its characteristics during the fasting month of
- Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001
- 276 (EPIDIAR) study. Diabetes Care 2004;27:2306–11.
- 277 https://doi.org/10.2337/diacare.27.10.2306.

- [8] Lee SWH, Lee JY, Tan CSS, Wong CP. Strategies to Make Ramadan Fasting Safer in
- 279 Type 2 Diabetics: A Systematic Review and Network Meta-analysis of Randomized
- 280 Controlled Trials and Observational Studies. Medicine (Baltimore) 2016;95.
- [9] Gad H, Hayat T, Al-Muhannadi H, Malik BR, Mussleman P, Malik RA. Efficacy and
- safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A
- systematic review and meta-analysis. Diabetes Res Clin Pract 2021;172:108562.
- 284 https://doi.org/10.1016/j.diabres.2020.108562.
- [10] Gad H, Al-Muhannadi H, Purra H, Mussleman P, Malik RA. The effect of Ramadan
- focused education on patients with type 2 diabetes: A systematic review and meta-
- analysis. Diabetes Res Clin Pract 2020;162:108122.
- 288 https://doi.org/https://doi.org/10.1016/j.diabres.2020.108122.
- [11] Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA
- 200 2020 explanation and elaboration: updated guidance and exemplars for reporting
- 291 systematic reviews. BMJ 2021;372:n160. https://doi.org/10.1136/bmj.n160.
- 292 [12] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a
- revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:14898.
- 294 https://doi.org/10.1136/bmj.l4898.
- [13] Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JPT. Evaluating the
- 296 Quality of Evidence from a Network Meta-Analysis. PLoS One 2014;9:e99682.
- 297 [14] Begg CB, Mazumdar M. Operating Characteristics of a Rank Correlation Test for
- 298 Publication Bias. Biometrics 1994;50:1088. https://doi.org/10.2307/2533446.
- [15] Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
 graphical test. BMJ 1997;315:629–34. https://doi.org/10.1136/bmj.315.7109.629.
- 301 [16] Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of
- 302 methods. Stat Med 1999;18:2693–708. https://doi.org/10.1002/(SICI)1097-
- 303 0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V.
- Wan Seman WJ, Kori N, Rajoo S, Othman H, Mohd Noor N, Wahab NA, et al. Switching
 from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of
- Ramadan is associated with a reduction in hypoglycaemia. Diabetes, Obes Metab

- 307 2016;18:628–32. https://doi.org/10.1111/dom.12649.
- 308 [18] Malha LP, Taan G, Zantout MS, Azar ST. Glycemic effects of vildagliptin in patients with
- 309type 2 diabetes before, during and after the period of fasting in Ramadan. Ther Adv

310 Endocrinol Metab 2014;5:3–9. https://doi.org/10.1177/2042018814529062.

311 [19] Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during

Ramadan fasting. Diabetes Res Clin Pract 2002;58:45–53. https://doi.org/10.1016/S01688227(02)00104-3.

314 [20] Hassanein MM, Sahay R, Hafidh K, Djaballah K, Li H, Azar S, et al. Safety of

lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2

diabetes mellitus who elect to fast during Ramadan (LixiRam): An international,

randomized, open-label trial. Diabetes Res Clin Pract 2019;150:331–41.

- 318 https://doi.org/10.1016/j.diabres.2019.01.035.
- 319 [21] Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including
- frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin
- and gliclazide in patients with type 2 diabetes fasting during Ramadan: The STEADFAST
- study. Vasc Health Risk Manag 2014;10:319–26. https://doi.org/10.2147/VHRM.S64038.
- 323 [22] Brady EM, Davies MJ, Gray LJ, Saeed MA, Smith D, Hanif W, et al. A randomized
- 324 controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add
- on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4
- Ramadan Trial. Diabetes, Obes Metab 2014;16:527–36.
- 327 https://doi.org/10.1111/dom.12249.

Azar ST, Echtay A, Wan Bebakar WM, Al Araj S, Berrah A, Omar M, et al. Efficacy and
safety of liraglutide compared to sulphonylurea during <scp>R</scp> amadan in patients
with type 2 diabetes (<scp>LIRA□R</scp> amadan): a randomized trial. Diabetes, Obes

- 331 Metab 2016;18:1025–33. https://doi.org/10.1111/dom.12733.
- 332 [24] Aravind SR, Ismail SB, Balamurugan R, Gupta JB, Wadhwa T, Loh SM, et al.

Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with

- sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med
- Res Opin 2012;28:1289–96. https://doi.org/10.1185/03007995.2012.707119.
- 336 [25] Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman Boehm I, Kaddaha G, et al.

- 337 The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with
- sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract
- 339 2011;65:1132–40. https://doi.org/10.1111/j.1742-1241.2011.02797.x.
- 340 [26] Gad H, Al-Nassr N, Mohammed I, Khan A, MacDonald R, Mussleman P, et al. Effect of
- Ramadan fasting in patients with type $\Box 2$ diabetes mellitus treated with sodium-glucose
- cotransporter 2 inhibitors: A systematic review and meta-analysis. J Diabetes Investig
- 343 2022;13:822–9. https://doi.org/10.1111/jdi.13741.
- 344 [27] Shiju R, Akhil A, Thankachan S, Tuomilehto J, Al Arouj M, Bennakhi A. Safety
- Assessment of Glucose-Lowering Drugs and Importance of Structured Education during
- Ramadan: A Systematic Review and Meta-Analysis. J Diabetes Res 2022;2022:3846253.
- 347 https://doi.org/10.1155/2022/3846253.
- Loh HH, Yee A, Loh HS, Sukor N, Kamaruddin NA. Comparative studies of dipeptidyl
 peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast
 in the month of Ramadan: A systematic review and meta-analysis. Prim Care Diabetes
 2016;10:210–9. https://doi.org/10.1016/j.pcd.2015.09.001.
- 352 [29] Halimi S, Levy M, Huet D, Quéré S, Dejager S. Experience with Vildagliptin in Type 2
- 353 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study.
- 354 Diabetes Ther Res Treat Educ Diabetes Relat Disord 2013;4:385–98.
- 355 https://doi.org/10.1007/s13300-013-0038-7.
- 356 [30] Hassanein M, Hanif W, Malik W, Kamal A, Geransar P, Lister N, et al. Comparison of the
- 357 dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in
- combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting
- during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011;27:1367–74.
- 360 https://doi.org/10.1185/03007995.2011.579951.
- [31] Gray LJ, Dales J, Brady EM, Khunti K, Hanif W, Davies MJ. Safety and effectiveness of
 non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who
 observe Ramadan: a systematic review and meta-analysis. Diabetes Obes Metab
- 364 2015;17:639–48. https://doi.org/10.1111/dom.12462.
- [32] Mbanya JC, Al-Sifri S, Abdel-Rahim A, Satman I. Incidence of hypoglycemia in patients
 with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A

- 367 meta-analytical approach. Diabetes Res Clin Pract 2015;109:226–32.
- 368 https://doi.org/10.1016/j.diabres.2015.04.030.
- 369 [33] Bonakdaran SH, Khajeh-Dalouie M. The effects of fasting during Ramadan on glycemic
- excursions detected by continuous glucose monitoring system (CGMS) in patients with
- 371 type 2 diabetes. Med J Malaysia 2011;66:447–50.
- 372 [34] John M, Cerdas S, Violante R, Deerochanawong C, Hassanein M, Slee A, et al. Efficacy
- and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.

374 Int J Clin Pract 2016;70:775–85. https://doi.org/10.1111/ijcp.12868.

- 375 [35] Tootee A, Esfahani EN, Larijani B. Diabetes management during Ramadan amid Covid376 19 pandemic. DARU J Pharm Sci 2020;28:795–8. https://doi.org/10.1007/s40199-020-
- 377 00357-6.
- 378 [36] Hassanein M, Echtay A, Hassoun A, Alarouj M, Afandi B, Poladian R, et al. Tolerability
- of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results
 of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). Int J Clin
 Pract 2017;71. https://doi.org/10.1111/ijcp.12991.
- 382 [37] Bashier A, Khalifa AA, Abdelgadir EI, Al Saeed MA, Al Qaysi AA, Bayati MBA, et al.
- 383 Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of
- Ramadan in Muslim Patients with Type 2 Diabetes. Oman Med J 2018;33:104–10.
- 385 https://doi.org/10.5001/omj.2018.21.
- 386[38]Tang L, Chang SJ, Chen C-J, Liu J-T. Non-Invasive Blood Glucose Monitoring
- 387 Technology: A Review. Sensors (Basel) 2020;20. https://doi.org/10.3390/s20236925.

388

389 Figures' legends

Figure 1: The PRISMA flow diagram of the study selection process.

391 Figure 2: Network plots of all included studies for: i) antidiabetic drug class and symptomatic 392 hypoglycemia, ii) antidiabetic drug class and any adverse effects, iii) drug name and symptomatic 393 hypoglycemia.

Figure 3: Non-insulin antidiabetics network meta-analysis results with corresponding GRADE (grading of recommendations, assessment, development, and evaluation) certainty of the evidence for symptomatic hypoglycemia. Values correspond to the relative risk of having at least one symptomatic hypoglycemic event when comparing columns and rows during Ramadan. Values in bold indicate a statistically significant treatment effect. Values under the treatment's names correspond to the P-scores for the network ranking.

Figure 4: Non-insulin antidiabetics network meta-analysis results with corresponding GRADE (grading of recommendations, assessment, development, and evaluation) certainty of the evidence for symptomatic hypoglycemia. Values correspond to the relative risk of having at least one symptomatic hypoglycemic event when comparing columns and rows during Ramadan. Values in bold indicate a statistically significant treatment effect. Values under the treatment's names correspond to the P-scores for the network ranking.

Figure 5: Non-insulin antidiabetics network meta-analysis results with corresponding GRADE (grading of recommendations, assessment, development, and evaluation) certainty of the evidence for any adverse events. Values correspond to the relative risk of having any adverse event when comparing column and row during Ramadan. Values in bold indicate a statistically significant treatment effect. Values under the

treatment's names correspond to the P-scores for the network ranking.

Figure 6: Network plots and sensitivity network meta-analysis results with corresponding GRADE (grading of recommendations, assessment, development, and evaluation) certainty of the evidence for symptomatic hypoglycemia. Values correspond to the relative risk of having at least one symptomatic hypoglycemic event when comparing columns and rows during Ramadan. Values in bold indicate a statistically significant treatment effect. Values under the treatment's names correspond to the P-scores for

the network ranking.




Figure 1 | The PRISMA flow diagram of the study selection process




Figure 2 | Network plots of all included studies for: i) antidiabetic drug class and symptomatic hypoglycemia, ii) antidiabetic drug class and any adverse effects, iii) drug name and symptomatic hypoglycemia.

0.58 (0.12 to 2.85)	SGL2 (0.909)				
⊕⊕⊕ ⊕⊕⊕ (0.483) 0.20 (0.03 to 1.11) 0.34 (0.11 to 1.004) 0.62 (0.24 to 1.62) Meglitinide ⊕⊕⊕ ⊕⊕⊕ ⊕⊕⊕ (0.201) 0.18 (0.04 to 0.78) 0.31 (0.17 to 0.56) 0.57 (0.43 to 0.75) 0.91 (0.36 to 2.28) Sulphonylurea					
⊕⊕⊕ ⊕⊕⊕ ⊕⊕⊕ (0.201) 0.18 (0.04 to 0.78) 0.31 (0.17 to 0.56) 0.57 (0.43 to 0.75) 0.91 (0.36 to 2.28) Sulphonylurea		· · · · · · · · · · · · · · · · · · ·	551 1		
		× /		U	
		· · · · · · · · · · · · · · · · · · ·			· ·

High certainty Moderate certainty Low certainty Very low certainty

Figure 3 | Non-insulin antidiabetics network meta-analysis results with corresponding GRADE (grading of recommendations, assessment, development, and evaluation) certainty of the evidence for symptomatic hypoglycemia. Values correspond to the relative risk of having at least one symptomatic hypoglycemic event when comparing columns and rows during Ramadan. Values in bold indicate a statistically significant treatment effect. Values under the treatment's names correspond to the P-scores for the network ranking


Dapagliflozin (0.874)						
0.73 (0.12 to 4.44) ⊕	Lixisenatide (0.813)					
0.53 (0.10 to 2.71) ⊕	0.73 (0.20 to 2.60) ⊕	Liraglutide (0.715)				
0.35 (0.08 to 1.58) ⊕	0.48 (0.16 to 1.46) ⊕	0.66 (0.30 to 1.45) ⊕	Sitagliptin (0.515)			
0.24 (0.05 to 1.16) ⊕⊕	0.34 (0.10 to 1.09) ⊕⊕	0.46 (0.19 to 1.12) ⊕⊕	0.70 (0.38 to 1.29) ⊕⊕⊕	Vildagliptin (0.297)		
0.20 (0.03 to 1.11) ⊕⊕	0.27 (0.07 to 1.10) ⊕⊕	0.37 (0.12 to 1.19) ⊕⊕	0.56 (0.21 to 1.49) ⊕⊕⊕	0.80 (0.28 to 2.30) ⊕⊕	Repaglinide (0.193)	
0.18 (0.04 to 0.78) ⊕⊕⊕	0.25 (0.09 to 0.71) ⊕⊕⊕	0.34 (0.17 to 0.69) ⊕⊕⊕	0.51 (0.37 to 0.71) ⊕⊕⊕⊕	0.73 (0.44 to 1.23) ⊕⊕⊕⊕	0.91 (0.36 to 2.28) ⊕⊕	Sulphonylurea (0.093)

High certainty Moderate certainty Low certainty Very low certainty

Figure 4 | Non-insulin antidiabetics network meta-analysis results with corresponding GRADE (grading of recommendations, assessment, development, and evaluation) certainty of the evidence for symptomatic hypoglycemia. Values correspond to the relative risk of having at least one symptomatic hypoglycemic event when comparing columns and rows during Ramadan. Values in bold indicate a statistically significant treatment effect. Values under the treatment's names correspond to the P-scores for the network ranking.

Sulphonylurea (0.585)			
1.00 (0.47 to 2.15) ⊕⊕⊕	SGL2 (0.555)		
0.94 (0.50 to 1.79) ⊕⊕⊕⊕	0.94 (0.35 to 2.55) ⊕⊕⊕	DDP-4 (0.485)	
$\begin{array}{c} 0.88 (0.52 \text{ to } 1.48) \\ \oplus \oplus \oplus \end{array}$	0.87 (0.35 to 2.20) ⊕⊕⊕	0.93 (0.40 to 2.12) ⊕⊕⊕	GLP-1 (0.375)
	-		

Figure 5 | Non-insulin antidiabetics network meta-analysis results with corresponding GRADE (grading of recommendations, assessment, development, and evaluation) certainty of the evidence for any adverse events. Values correspond to the relative risk of having any adverse event when comparing column and row during Ramadan. Values in bold indicate a statistically significant treatment effect. Values under the treatment's names correspond to the P-scores for the network ranking.



Liraglutide (0.923)							
0.77 (0.12 to 5.10)	Lixisenatide (0.877)						
0.27 (0.06 to 1.22)	0.35 (0.08 to 1.47)	Sitagliptin (0.603)					
0.27 (0.05 to 1.54)	0.35 (0.06 to 1.90) ⊕	1.00 (0.28 to 3.57) ⊕	Vildagliptin (0.566)				
0.19 (0.05 to 0.79) ⊕⊕⊕	0.25 (0.06 to 0.96) ⊕⊕⊕	0.71 (0.32 to 1.54) ⊕⊕	0.71 (0.26 to 1.93) ⊕⊕	Gliclazide (0.404)	-		
0.15 (0.04 to 0.65) ⊕⊕⊕	0.20 (0.05 to 0.74) ⊕⊕⊕	0.57 (0.30 to 1.11) ⊕⊕⊕	0.57 (0.17 to 1.91) ⊕⊕	0.81 (0.42 to 1.57) ⊕⊕	Glimepiride (0.278)		
0.13 (0.02 to 0.84) 	0.16 (0.03 to 1.07) ⊕⊕	0.47 (0.11 to 1.93)	0.47 (0.08 to 2.68)	0.66 (0.16 to 2.76)	0.82 (0.20 to 3.26)	Repaglinide (0.232)	
0.12 (0.03 to 0.49) ⊕⊕⊕	0.15 (0.04 to 0.62) ⊕⊕⊕	0.43 (0.21 to 0.87) ⊕⊕⊕	0.43 (0.12 to 1.48) ⊕⊕⊕	0.61 (0.29 to 1.25) ⊕⊕	0.74 (0.39 to 1.42) ⊕⊕	0.91 (0.27 to 3.10) ⊕	Glibenelamide (0.117)

 High certainty
 Moderate certainty
 Low certainty
 Very low certainty

Figure 6

Table 1: Basic characteris	tics of included articles
----------------------------	---------------------------

Study ID	Intervention	on Intervention						Sulphonylurea					
	name	Total, n	Sympt. HG*	Age, mean (SD)	Females (%)	BMI, mean (SD)	Total, n	Sympt. HG	Age, mean (SD)	Females (%)	BMI, mean (SD)		
		ш		incan (SD)		incan (SD)			incan (BD)				
Al Sifri	Sitagliptin	507	34	55 ± 11	238 (46.9)	30.5 ± 5.7	514	68	55 ± 10	259 (50.39)	30.5 ± 5.6		
et al. 2011													
Aravind et al. 2012	Sitagliptin	421	16	51.4 ± 9.9	213 (50.59)	27.4 ± 6.0	427	31	50.7 ± 10.0	233 (54.57)	27.5 ± 4.7		
Azar	Liraglutide	171	5	54.9 ± 9.27	86 (50.3)	30.2 ± 5.37	170	16	54.0 ± 9.33	87 (51.2)	31.4 ± 5.88		
et al. 2016													
Brady	Liraglutide	47	12	51.5 ± 11.1	23 (48.94)	33.0 ± 7.3	52	24	52.2 ± 10.7	26 (50)	30.1 ± 4.3		
et al. 2013	plus metformin												
Hassanein	Vildagliptin	279	8	54.6 ± 9.3	147 (52.7)	30.7 ± 5.0	278	19	54.3 ± 9.1	150 (54.0)	31.1 ± 5.2		
et al. 2014													
Hassanein	Lixisenatide	92	3	52.6 ± 9.5	52 (56.5)	29.7 ± 5.3	92	8	54.1 ± 10.6	49 (53.3)	29.0 ± 4.3		
et al. 2019	+basal insulin												
Mafauzy et al. 2002	Repaglinide	116	8	52.7 ± 7.4	29 (25)	26.5 ± 2.5	119	9	54.5 ± 6.9	37 (31.1)	26.8 ± 3.2		
Malha	Vildagliptin	30	19	57.0 ± 9.6	NA	29.49 ± 4.66	39	26	54.6 ± 9.2	NA	28.90 ± 4.49		
et al. 2014													
Wan	Dapagliflozin	58	4	53 ± 9.1	23 (39.7)	29.9 ± 4.84	52	15	56 ± 9.1	21 (40.4)	29.64 ± 4.44		
Seman	+metformin												
et al. 2016													

*: Symptomatic